

1-8-2008

Sub-optimal pain control in patients with rheumatic disease.

Barry J. Sheane

St James's Hospital, Dublin

Frank Doyle

Royal College of Surgeons in Ireland, fdoyl4@rcsi.ie

Christina Doyle

St James's Hospital, Dublin

Ciara O'Loughlin

St James's Hospital, Dublin

Donough Howard

St James's Hospital, Dublin

See next page for additional authors

Citation

Sheane BJ, Doyle F, Doyle C, O'Loughlin C, Howard D, Cunnane G. Sub-optimal pain control in patients with rheumatic disease. *Clinical Rheumatology* 2008;27(8):1029-33.

This Article is brought to you for free and open access by the Department of Psychology at e-publications@RCSI. It has been accepted for inclusion in Psychology Articles by an authorized administrator of e-publications@RCSI. For more information, please contact epubs@rcsi.ie.

Authors

Barry J. Sheane, Frank Doyle, Christina Doyle, Ciara O'Loughlin, Donough Howard, and Gaye Cunnane

Attribution-Non-Commercial-ShareAlike 1.0

You are free:

- to copy, distribute, display, and perform the work.
- to make derivative works.

Under the following conditions:

- Attribution — You must give the original author credit.
- Non-Commercial — You may not use this work for commercial purposes.
- Share Alike — If you alter, transform, or build upon this work, you may distribute the resulting work only under a licence identical to this one.

For any reuse or distribution, you must make clear to others the licence terms of this work. Any of these conditions can be waived if you get permission from the author.

Your fair use and other rights are in no way affected by the above.

This work is licenced under the Creative Commons Attribution-Non-Commercial-ShareAlike License. To view a copy of this licence, visit:

URL (human-readable summary):

- <http://creativecommons.org/licenses/by-nc-sa/1.0/>

URL (legal code):

- <http://creativecommons.org/worldwide/uk/translated-license>
-

1 Clin Rheumatol
2 DOI 10.1007/s10067-008-0881-5

3 BRIEF REPORT

4 Sub-optimal pain control in patients with rheumatic disease

5 Barry J Sheane · Frank Doyle · Christina Doyle ·
6 Ciara O'Loughlin · Donough Howard · Gaye Cunnane

7 Received: 30 January 2008 / Revised: 12 February 2008 / Accepted: 12 March 2008
8 © Clinical Rheumatology 2008

11 **Abstract** The visual analog scale (VAS) of pain is a
12 ubiquitous clinical and research tool with widespread
13 application in the rheumatic diseases. The objectives of
14 this study were to assess if patients report pain differently to
15 doctors or nurses, to determine reproducibility of this test
16 for diagnosis, age, gender, and treatment, and to ascertain
17 the level of pain in patients attending general rheumatology
18 clinics. Using a standardized line of exactly 100 mm and
19 instructions with identical wording, consecutive patients
20 attending general rheumatology clinics were asked to score
21 their perceived level of pain in the preceding week. Two
22 assessments were carried out, one before and one after the
23 clinic visit, and each patient was questioned by both a
24 doctor and a nurse. Differences between the first and
25 second VAS scores (VAS1 and VAS2) were recorded. One
26 hundred and eight patients completed the study (69 female).
27 VAS1 and VAS2 scores were administered by a similar
28 number of doctors and nurses. There was no significant
29 difference between mean VAS1 and VAS2 scores (41.1 vs.
30 41.4 mm, $p=0.78$). VAS1 and VAS2 differed by <4 mm in
31 59% of patients. Age, gender, or diagnosis did not influence
32 VAS1 or VAS2. Differences in scores were independent of
33 which health professional administered the scale ($p=0.19$).
34 Patients taking painkillers had higher mean VAS scores
35 (49 mm) compared with those not on analgesia (27 mm; $p<$

0.001). Anti-rheumatic treatment did not influence pain 36
scores ($p=0.13$). The VAS is a reliable and effective 37
method of pain assessment. Results are independent of 38
which health professional administers the scale. Patients 39
with rheumatic disease report their pain similarly regardless 40
of diagnosis. However, pain control is sub-optimal in 41
patients taking analgesia. Specific assessment of pain is, 42
thus, important in patients attending rheumatology clinics. 43

Keywords Analgesia · Pain · Rheumatic disease · VAS 44

Introduction 45

Pain is a significant and dominant symptom for many 46
patients with rheumatic disease. However, the assessment 47
of treatment effectiveness is frequently made by objective 48
measures of inflammation or joint integrity rather than the 49
patient's perception of qualitative life improvement. Pain, 50
as a subjective symptom, is when a patient is having 51
difficulty to communicate to others and is affected by a 52
variety of psychosocial and demographic factors¹. Gender, 53
ethnicity, cigarette smoking, and educational levels are 54
thought to influence the reporting of pain by patients with 55
rheumatoid arthritis (RA) [1]. Patients have been shown to 56
complain different pain levels in separate outpatient clinics 57
held on the same day [2]. Thus, several variables may 58
influence the under-treatment or over-treatment of pain 59
adversely affecting the patient in the process. 60

It is not known if patients report pain differently to a 61
variety of health professionals. If nurses have more 62
dedicated time slots than physicians in a clinic setting, it 63
is possible that patients will complain more to the former 64
health professional. However, in our institution, doctors are 65
the sole prescribers of analgesia, suggesting that patients 66

B. J. Sheane (✉) · C. Doyle · C. O'Loughlin · D. Howard ·
G. Cunnane
Department of Rheumatology, St James's Hospital,
Dublin 8, Ireland
e-mail: sheaneb@yahoo.com

F. Doyle
Department of Psychology, Royal College of Surgeons in Ireland,
Dublin 2, Ireland

67 might be more likely to emphasize the severity of pain to
68 physicians rather than nurses.

69 The visual analog scale (VAS) is a validated tool for
70 measuring different variables, including pain [3–5]. When
71 compared with other scales, such as the numerical rating
72 scale and the verbal rating scale, it has been found that
73 results correlate closely [6–9].

74 The primary objective of this study was to ascertain
75 whether variability exists between individual patient pain
76 scores when the VAS is administered sequentially by
77 doctors and nurses. Secondly, we set out to establish the
78 reproducibility of the VAS for diagnosis, age, gender, and
79 treatment. Thirdly, we wanted to determine the level of pain
80 in patients attending general rheumatology clinics.

81 **Materials and methods**

82 Consecutive patients attending general rheumatology out-
83 patient clinics were asked to complete two horizontal visual
84 analog scales for pain. This consisted of marking a vertical
85 line across a horizontal line which measured exactly
86 100 mm. This mark was representative of their individual
87 pain levels for the previous 7 days. The VAS was
88 administered by both rheumatology nurses and doctors. If
89 a nurse-administered the first VAS (VAS1), a doctor would
90 administer the second VAS (VAS2), and vice versa. VAS1
91 was completed at the beginning of the clinic and VAS2
92 after the patient’s medical consultation.

93 Doctors and nurses delivered identically worded instruc-
94 tions to the patient for the completion of the VAS. These
95 were as follows: *This is a line that represents your pain*
96 *level over the last 7 days. This end is “no pain” over the*
97 *last 7 days (point to “Zero”) and this end (point to “100”) is*
98 *the “worst possible pain”. I want you to draw a vertical line*
99 *over the point on the scale that you think best represents*
100 *your pain level over the last 7 days.*

101 Patients were blinded from their first VAS score. Doctors
102 and nurses administering the VAS were prohibited from
103 demonstrating how to mark the scale, to prevent influenc-
104 ing patients’ scores.

105 Patients’ rheumatic diagnoses were recorded along with
106 age, gender, analgesia, and anti-rheumatic medication.
107 Patients who identified literacy difficulties were noted, but
108 direct questioning with regard to literacy was not pursued.

109 VAS scores were measured as the distance from “0” to
110 the vertical line placed by the patients along the scale. This
111 distance was measured in millimeters. Where a patient
112 placed an “X” over the VAS, rather than the vertical line as
113 instructed, the score was given as the point at which a
114 perpendicular line drawn from the crossover of the “X” fell
115 onto the scale. A note was made of the number of VAS

Table 1 Patient characteristics t1.1

	Number (%)	Mean	SD	t1.2
Patients	108 (100)			t1.3
Age		55.5	14.7	t1.4
Female	69 (63.9)			t1.5
DMARD* use	61 (56.5)			t1.6
Analgesic use	68 (62.9)			t1.7

DMARD Disease-modifying anti-rheumatic drug t1.8

completed incorrectly, i.e., placing a mark along the scale
other than the vertical line requested in the instructions. 116 117

Statistical analysis 118

Student’s *t*-test was used to compare VAS scores for
categorical variables, including gender, diagnosis, and the
health professional administering the VAS. Pearson’s test
was used to assess correlation for normally distributed data.
A mixed-model analysis of variance (ANOVA) was used to
examine for any effects of doctors or nurses on VAS scores
and for the effect of time on the VAS. SPSS 14.0 for
Windows was used to analyze the data. 119 120 121 122 123 124 125 126

Results 127

This was a cross-sectional study of patients with a variety
of rheumatic diseases attending a general rheumatology
clinic over a period of 4 weeks. All invited patients agreed
to participate in the study (*n*=108). Demographic, diagnos-
tic, and treatment data are outlined in Tables 1, 2, 3. 128 129 130 131 132

Table 2 Diagnostic groupings t2.1

	No.	Percentage (%)	t2.2
RA	38	35.2	t2.3
OA	15	13.9	t2.4
Spondyloarthritis	13	12.0	t2.5
Gout	3	2.8	t2.6
CTD	7	6.5	t2.7
Other	14	13.0	t2.8
Combination	18	16.7	t2.9
Total	108	100.0	t2.10

Spondyloarthritis included nine patients with psoriatic arthritis and
four with ankylosing spondylitis; CTD included three patients with
scleroderma, one SLE, one mixed connective tissue disease, one
Sjogren's syndrome and one Takayasu's arteritis; "Other" was
composed of fibromyalgia, polymyalgia rheumatica, regional pain
syndrome and lower back pain; "Combination" included those with
more than one rheumatic diagnosis
RA Rheumatoid arthritis, OA osteoarthritis, CTD connective tissue
disease t2.11

t3.1 **Table 3** Types and frequencies of analgesic medication

t3.2 Analgesic	No.	Percentage (%)
t3.3 Paracetamol	15	13.9
t3.4 NSAID	12	11.1
t3.5 Topical NSAID	1	.9
t3.6 Paracetamol/codeine (500 mg/8 mg)	14	13.0
t3.7 Paracetamol/codeine (500 mg/30 mg)	5	4.6
t3.8 Tramadol	1	.9
t3.9 Any combination	18	16.7
t3.10 Other (nerve block, strong opiate)	2	1.9
t3.11 No analgesia	40	37.0
t3.12 Total	108	100.0

t3.13 NSAID Non-steroidal anti-inflammatory drug

133 All patients were fluent in English and demonstrated
 134 good understanding of the instructions given. There was a
 135 time difference of approximately 30 min between the
 136 completion of VAS1 and VAS2 during which the patient
 137 underwent a thorough clinical evaluation. The means of
 138 VAS1 and VAS2 scores were 41.1 and 41.4 mms, respec-
 139 tively ($p=0.78$; Table 4).

140 VAS1 and VAS2 scores correlated strongly (Pearson
 141 correlation coefficient 0.898, $p<0.001$; Fig. 1). Most
 142 patients complained of pain (mean VAS score=41.3 mm
 143 ([VAS1 + VAS2]/2), range 0–100 mm). There was a
 144 relatively even distribution of mean VAS scores among
 145 the study population (Fig. 2).

146 VAS and health professionals

147 VAS1 and VAS2 were administered by an equivalent
 148 number of nurses and doctors (Table 4). When a doctor

t4.1 **Table 4** Mean and median values of the VAS scores

t4.2	No. (%)	Mean (mm)	Median (mm)	SD (mm)	P value
t4.3 VAS1	108 (100)	41.1	41.0	27.4	0.78
t4.4 VAS2	108 (100)	41.4	38.5	27.0	
t4.5 VAS1 by doctors	53 (49.1)	38.1	37.0	26.9	0.26
t4.6 VAS1 by nurses	55 (50.9)	44.1	46.0	27.7	
t4.7 VAS2 by doctors	55 (50.9)	42.9	39.0	27.1	0.58
t4.8 VAS2 by nurses	53 (49.1)	39.9	36.0	27.2	
t4.9 VAS1 + VAS2 ^a					
t4.10 Doctors	108 (100)	40.1	38.5	26.9	0.67
t4.11 Nurses	108 (100)	42.1	39.0	27.4	
t4.12 VAS2-VAS1 ^b					
t4.13 Doctors ^c	53 (49.1)	1.92	0.0	8.9	0.19
t4.14 Nurses ^c	55 (50.9)	-1.22	1.0	14.7	

t4.15 ^aVAS1 + VAS2 represents the mean of all VAS scores administered by doctors and by nurses

^bVAS2 - VAS1 refers to the difference between VAS1 and VAS2

^cHealth professional administering VAS1

administered VAS1, a nurse-administered VAS2 and vice versa. No significant difference was observed between VAS scores administered by doctors or nurses. The mean of all VAS scores administered by doctors was 40.1 mm while the mean for VAS scores administered by nurses was 42.1 mm ($p=0.67$). The mean score for doctor-administered VAS1 was 38.1 mm in comparison with 44.1 mm for nurse-administered VAS1 ($p=0.26$). The mean of VAS2 administered by doctors was 42.9 mm and 39.9 mm by nurses ($p=0.58$).

VAS and rheumatic diagnosis

VAS scores did not differ significantly between rheumatic diagnoses. The largest diagnostic cohort comprised RA ($n=38$), while 13.9% had osteoarthritis and 12% seronegative spondyloarthritis. A variety of other rheumatic diseases were also represented and are detailed in Table 2. There was no significant difference in VAS scores between ‘inflammatory’ (RA, spondyloarthropathy) and ‘non-inflammatory’ diseases ($p=0.76$).

VAS and medication use

Table 3 outlines the number of patients prescribed a variety of analgesics. Forty patients were not using any painkillers or anti-inflammatory drugs, while 68 were taking daily analgesics, either single agents or a combination of products. VAS scores were significantly higher in those patients taking analgesics (mean VAS score 49.5 mm) in comparison with patients using none (mean VAS score 27.4 mm; $p<0.001$; Fig. 3). Patients taking a combination of analgesics had higher VAS scores (mean VAS 58.5 mm) compared with those using single analgesic agents (mean




Fig. 1 The plot is linear signifying correlation between VAS1 and VAS2 scores

179 VAS 46 mm). However, this difference did not reach
180 statistical significance ($p=0.1$).

181 Sixty-one patients were taking disease-modifying anti-
182 rheumatic drugs (DMARD), either as single agents ($n=20$)
183 or in combination ($n=41$). Mean VAS scores were 35.8 mm
184 for those prescribed one DMARD and 45.9 mm for those
185 on combination treatment. However, no significant differ-
186 ence was observed ($p=0.13$).

187 VAS and age and gender

188 Age had no influence on VAS1 or VAS2 scores ($p=0.51$
189 and 0.89, respectively). There was no correlation between
190 age and the difference between VAS1 and VAS2 ($p=0.18$).

191 The mean VAS1 score for males was 37.2 and 43.4 mm
192 for females ($p=0.26$) while mean VAS2 scores were 38.5
193 and 43.1 mm for males and females, respectively ($p=0.40$).
194 These VAS scores were not influenced by which health
195 professional administered the test ($p>0.5$). Differences in
196 VAS scores, [VAS2-VAS1], between males and females
197 were not significant ($p=0.51$).




Fig. 2 The distribution of mean VAS scores $([VAS1 + VAS2]/2)$ and the proportion of patients within each of the VAS ranges




Fig. 3 This bar graph highlights the difference in mean VAS scores between those taking and not taking analgesia ($p<0.001$)

VAS and Literacy

Two patients identified themselves as having poor literacy skills. The first patient had a 20+ mm discrepancy between VAS1 and VAS2. The second patient marked the scale incorrectly, but both VAS1 and VAS2 correlated.

Sixteen patients (14.8%) marked the VAS incorrectly by placing an “X” on the scale or a mark that did not conform to the vertical line requested in the instructions. While those who marked the VAS incorrectly had a tendency to rate their pain at the 50% range (mean VAS1 and VAS2 of 51.1 and 52.3 mm, respectively), compared to those correctly marking the VAS (39.4 and 39.6 mm), this was not significant ($p=0.11$ for VAS1; $p=0.08$ for VAS2).

There was no significant difference between the means of [VAS2-VAS1] for those marking the VAS correctly and incorrectly ($p=0.76$).

Discussion

This study assessed the reliability of the visual analog scale of pain in patients attending general rheumatology clinics. The results were not influenced by which health professional administered the test and scores were similar regardless of age, gender, and rheumatic diagnosis.

Most patients in this study reported joint pain. However, levels of pain did not differ significantly between rheumatic diagnoses or with DMARD use. Where joint integrity is preserved, but inflammation is present, the dominant symptom may be ‘stiffness’ rather than severe pain. Thus, a VAS of joint stiffness may be a better symptom discriminator between rheumatic diseases.

Patients taking analgesia reported higher pain levels than those who were not using painkillers or non-steroidal anti-

229 inflammatory drugs. This suggests that pain control in those
 230 prescribed analgesia in the outpatient setting is inadequate.
 231 As there are several modes of action for different
 232 analgesics, closer attention should be paid to the efficacy
 233 of pain management in rheumatology clinics.

234 Literacy may influence the ability to complete a VAS
 235 [10]. Although such skills were not formally tested in this
 236 study, 15% of patients did not complete the test according
 237 to the carefully worded instructions, suggesting that this
 238 issue should be taken into account when using this type of
 239 measurement.

240 Completing two VAS tests within a short time frame
 241 may suggest that the second result could be influenced by
 242 the first, in what has been called the halo effect [7].
 243 However, all of the patients in this study underwent a
 244 thorough clinical assessment between VAS1 and VAS2,
 245 thus, reducing the likelihood of this phenomenon.

246 This study demonstrates that the VAS is an accurate
 247 measure of pain in patients with rheumatic disease and is
 248 reproducible regardless of whether it is administered by a
 249 doctor or nurse. It is not influenced by age, gender,
 250 diagnosis, or DMARD treatment. However, literacy and
 251 educational level may affect the ability to understand and
 252 complete the VAS instructions and should be taken into
 253 account in future studies using this assessment tool. Higher
 254 pain scores were reported in patients taking analgesics
 255 suggesting that pain control may be sub-optimal. Traditional
 256 outcomes in the treatment of rheumatic disease
 257 include the reduction of inflammation and joint destruction.

However, the VAS has an important role in ensuring that 258
 pain levels are also optimally suppressed. 259

References 260

1. Wolfe F, Michaud K (2007) Assessment of pain in rheumatoid 261
 arthritis: minimal clinically significant difference, predictors, and the 262
 effect of anti-tumor necrosis factor therapy. *J Rheum* 34:1674–1683 263
2. Reyes-Gibby CC, McCrory LL, Cleeland CS (2003) Variations in 264
 patients' self-report of pain by treatment setting. *J Pain Symptom* 265
Manage 25:444–448 266
3. Kelly AM (2001) The minimum clinically significant difference in 267
 visual analogue scale pain score does not differ with severity of 268
 pain. *Emerg Med J* 18:205–207 269
4. Gallagher EJ, Liebman M, Bijur PE (2001) Prospective validation 270
 of clinically important changes in pain severity measured on a 271
 visual analogue scale. *Ann Emerg Med* 38:633–638 272
5. Tjihuis GJ, Kooiman KG, Zwinderman AH et al (2003) 273
 Validation of a novel satisfaction questionnaire for patients with 274
 rheumatoid arthritis receiving outpatient clinical nurse specialist 275
 care, inpatient care, or day patient team care. *Arthritis Care &* 276
Res 49:193–199 277
6. Clark P, Lavielle P, Martinez H (2003) Learning from pain scales: 278
 patient perspective. *J Rheum* 30:1584–1588 279
7. Downie WW, Leatham PA, Rhind VM et al (1978) Studies with 280
 pain rating scales. *Ann Rheum Dis* 37:378–381 281
8. Joos E, Peretz A, Beguin S (1991) Reliability and reproducibility 282
 of visual analogue scale and numeric rating scale for therapeutic 283
 evaluation of pain in rheumatic patients. *J Rheum* 18:1269–1270 284
9. Huskisson EC (1974) Measurement of pain. *Lancet* 2:1127–1131 285
10. Ferraz MB, Quaresma MR, Aquino LRL et al (1990) Reliability 286
 of pain scales in the assessment of literate and illiterate patients 287
 with rheumatoid arthritis. *J Rheum* 17:1022–1024 288